Literature DB >> 6948734

Induction of tumor resistance by hybrid cell lines between human acute lymphocytic leukemia cells and mouse myeloma cells.

K Isobe, K Kawashima, E Watanabe, K Yamada, Y Nagai, I Nakashima.   

Abstract

Three hybrid cell lines were derived from the fusion of BALB/c mouse NS-1 myeloma cells and human acute lymphocytic leukemia cells. Hybrid clones contained almost all of the mouse chromosomes and a few human chromosomes, and induced tumors in BALB/c and BALB/c nu/nu mice when inoculated subcutaneously. However, the tumors of BALB/c mice subsided spontaneously within one month. The mice which survived the inoculation of 5 approximately 10 X 10(6) hybrid cells were able to reject a subsequent challenge with 5 X 10(6) NS-1 cells. Spleen cells or lymph node cells from immune mice were injected into BALB/c mice. These mice lived longer than the mice which received normal spleen cells or normal lymph node cells, when challenged with 5 X 10(6) NS-1 cells. These results suggest that a rearrangement of tumor-specific antigens on human/mouse hybrid cells can induce immunogenicity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6948734

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  1 in total

1.  Induction of high-grade anti-tumor immunity by use of a recombinant H-2Kb/avian erythroblastosis virus erbB gene transfectant.

Authors:  L N Ding; K Isobe; T Yoshida; K Kawashima; I Nakashima
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.